PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE

Autor:	S. Teitsson, A. Amadi, A. Kouloumenta, F. Diamantogiannis, I. Orsini, M. Augusto
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Cost effectiveness Health Policy Melanoma medicine.medical_treatment Public Health Environmental and Occupational Health Disease medicine.disease Complete resection Internal medicine Medicine Lymph Nivolumab business Adjuvant
Zdroj:	Value in Health. 22:S473
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d6dd69fcbef949ce0371075e49e8fa51 https://doi.org/10.1016/j.jval.2019.09.388 Zobrazit plný text záznamu Full Text from ScienceDirect